Revenue remains nil across the reported periods while operating losses have widened, reaching -$7.5M in 2026Q3 against R&D expense of $4.4M and SG&A of $3.0M, indicating no commercial offset to clinical spending.
Monopar Therapeutics Inc. (MNPR) annual income statement — 11-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 |
|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | 25.49M | 16.7M | 16.16M | 8.83M | 10.54M | 9.13M | 6.51M | 4.32M | 3.4M | 16.6M | 1.19M | 688.56K |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 1.75B | 6.8B | 3.16M | 3.23M | 2.95M | 2.63M | 2.44M | 2.36M | 1.63M | 1.17M | 912.47K | 587.08K |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 16.63M | 9.9B | 13.01M | 5.6M | 7.59M | 6.49M | 4.07M | 1.97M | 1.77M | 935.32K | 280.36K | 101.49K |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | -1000K | -16.69B | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14.5M | 0 | 0 |
| Operating Income | -25.49M | -16.7M | -16.16M | -8.83M | -10.54M | -9.13M | -6.51M | -4.32M | -3.4M | -16.6M | -1.19M | -689K |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -3.36% | -83.01% | 16.19% | -15.44% | -40.23% | -50.54% | -27.06% | 79.5% | -1291.9% | -73.12% | - |
| EBITDA | -20.6M | -13.72M | -15.59M | -8.4M | -10.52M | -9.1M | 0 | -4.22M | -71.85K | -14.5M | 0 | -438 |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -2.52% | 11.99% | -85.5% | 20.1% | -15.52% | - | 100% | -5779.89% | 99.5% | - | 100% | - |
| D&A (Non-Cash Add-back) | 0 | 0 | 0 | 0 | 0 | 0 | 6.51M | 0 | 3.33M | 2.1M | 1.19M | 688.56K |
| EBIT | -20.6M | -13.72M | -15.59M | -8.4M | -10.52M | -9.1M | -6.51M | -4.22M | -3.33M | -16.55M | -1.18M | -687K |
| Net Interest Income | 4.86M | 2.99M | 404.02K | 429.04K | 21.24K | 24.02K | 81.9K | 98.89K | 0 | 0 | 0 | 0 |
| Interest Income | 4.86M | 2.99M | 404.02K | 429.04K | 21.24K | 24.02K | 81.9K | 98.89K | 103.22K | 48.26K | 7.23K | 1.25K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 103.22K | 48.26K | 7.23K | 0 |
| Other Income/Expense | 4.89M | 2.99M | 575.3K | 429.04K | 21.24K | 24.02K | 204.3K | 98.89K | 31.15K | 48.26K | 7.23K | 1.25K |
| Pretax Income | -20.6M | -13.72M | -15.59M | -8.4M | -10.52M | -9.1M | -6.3M | -4.22M | -3.3M | -16.55M | -1.18M | -687K |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -71.61K | 0 | 800 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 2.17% | 0% | -0.07% | 0% |
| Net Income | -20.6M | -13.72M | -15.59M | -8.4M | -10.52M | -9.1M | -6.3M | -4.22M | -3.23M | -16.55M | -1.19M | -687K |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | -5.98% | 11.99% | -85.5% | 20.1% | -15.52% | -44.39% | -49.23% | -30.88% | 80.5% | -1296.34% | -72.58% | - |
| Net Income (Continuing) | -20.6M | -13.72M | -15.59M | -8.4M | -10.52M | -9.1M | -6.3M | -4.22M | -3.23M | -16.55M | -1.19M | -687K |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -2.41 | -1.85 | -1.36 | -0.58 | -0.83 | -0.73 | -0.58 | -0.40 | -0.31 | -1.59 | -0.12 | -0.08 |
| EPS Growth % | -19.44% | -36.03% | -134.48% | 30.12% | -13.7% | -25.86% | -45% | -29.03% | 80.5% | -1225% | -42.52% | - |
| EPS (Basic) | - | -1.85 | -1.36 | -0.58 | -0.83 | -0.73 | -0.58 | -0.40 | -0.31 | -1.59 | -0.12 | -0.08 |
| Diluted Shares Outstanding | 8.56M | 7.41M | 11.48M | 14.51M | 12.72M | 12.47M | 10.96M | 10.59M | 10.42M | 10.42M | 9.86M | 8.16M |
| Basic Shares Outstanding | 8.56M | 7.41M | 11.44M | 14.51M | 12.72M | 12.47M | 10.96M | 10.59M | 10.42M | 10.42M | 9.85M | 8.16M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying MNPR stock.
For fiscal year 2025, Monopar Therapeutics Inc. (MNPR) reported total revenue of $0.0M.
Monopar Therapeutics Inc. (MNPR) reported a net loss of $13.7M for the fiscal year ending 2025.
Key Metrics
Top Statement Risk
Ongoing clinical cash burn
Metrics are mathematically derived from official filings.
Losses Widening Without Revenue Offset
Based on reported quarterly income statements, MNPR has recorded zero revenue across all ten periods, with operating losses swinging from -$1.6M in 2024Q3 to -$11.1M in 2024Q4 and reaching -$7.5M in 2026Q3.
The absence of any top-line revenue means the trajectory is defined entirely by expense growth rather than commercial scaling. The pattern of lumpy R&D spend, including a $9.9M quarter in 2024Q4, suggests clinical program timing rather than a steady operating cadence. Investors should treat the trend as a function of trial activity and monitor whether losses moderate as programs mature.
R&D Drives the Entire Expense Base
As reported in the income statement, research and development expense accounts for nearly all operating spend, running between $984.3K and $9.9M per quarter, while SG&A stays in a narrower $590.6K to $3.0M band.
R&D dominance is consistent with a company advancing Validive and Camsirubicin through clinical stages, where enrollment and site costs dictate quarterly variance. SG&A has stepped up alongside the 2026 quarters, which may reflect pre-commercial or corporate infrastructure build-out, though the data alone does not confirm the purpose. Expense discipline cannot be fully judged without knowing how much of R&D is externally contracted.
Net Losses Track Operating Losses Closely
Based on reported figures, net loss has tracked operating loss closely across the period, with 2026Q3 showing -$6.2M net against -$7.5M operating, and EPS deteriorating to -$0.72 in the most recent quarter.
The small gap between operating and net loss suggests limited non-operating income or tax effects are distorting reported earnings. Stock-based compensation is modest relative to losses, so dilution-related quality concerns appear secondary to the underlying cash burn. Share count changes should be checked against EPS to separate loss growth from equity issuance effects.
2024Q4 Spike Marks Program Escalation
According to the reported quarterly figures, the 2024Q4 period stands out with R&D jumping to $9.9M from roughly $1.1M the prior quarter, lifting the operating loss to -$11.1M and EPS to -$0.95.
This step-change in R&D appears to coincide with clinical program escalation, though the income statement alone cannot identify the specific trials responsible. The quarter represents the sharpest single-period loss in the dataset and set a higher expense base that subsequent quarters have only partially unwound. Its lasting effect is a structurally higher burn level that investors should weigh against remaining cash runway.
Expense Growth Without Commercial Traction
Based on the reported income statements, the bear case rests on sustained operating losses of roughly -$5M to -$7M per quarter in 2026 with no revenue to offset them, implying continued dependence on external capital.
A skeptic would argue that absent revenue, each additional clinical quarter compounds losses without proof of commercial viability, and that the rising SG&A trend in 2026 adds overhead before any product is approved. Negative return on equity reinforces that capital has not yet generated returns. This analysis is inferential, and the conclusion depends on clinical outcomes not captured in the financial data provided.